Please tell us what you thought about today’s presentation by taking the survey below:
Residual symptoms of depression are very common in patients who are classified as being in response or even remission. In individuals with residual symptoms, we see an increased risk of functional & interpersonal impairments, as well as a significantly increased risk for recurrence of depression. For many patients, residual symptoms can persist for months after an episode of Major Depressive Disorder (MDD) and can be complicated by a host of co-occurring medical conditions, leaving health care providers and patients frustrated and searching for effective treatment strategies.
Please join PsychU for a brainstorming panel discussion featuring pre-eminent leaders in mental health. Listen in as moderator, John Awad, MD – Senior Clinical and Science Liaison at Otsuka Pharmaceuticals, discusses MDD unresolved symptoms with an expert panel. They will identify treatment goals in MDD patients with a focus on partial response and unresolved/residual symptoms, review most common residual symptoms in MDD, and highlight some complexities associated with residual symptoms in depression.
Chief wellness executive, Northwestern Medicine Director of Faculty Wellness, Northwestern University
Esteemed psychiatrist, Chief Medical Officer of The American Foundation for Suicide Prevention, and PsychU MDD Section Advisor.
Senior Medical Science Liaison
Speakers Guarava Agrawal, MD and Christine Moutier, MD are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Speaker John Awad is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Notifications
